What is the address of Dr. Katleen Bruylant - Neurologie & Revalidatie?

The registered office of Dr. Katleen Bruylant - Neurologie & Revalidatie is located at Maurice Maeterlinckstraat 14, 9000 Gent.

Is Dr. Katleen Bruylant - Neurologie & Revalidatie still active?

Yes. According to the CBE (2 November 2026) Dr. Katleen Bruylant - Neurologie & Revalidatie is active, legal situation “Normale toestand”, started on 20 January 2020.

Is Dr. Katleen Bruylant - Neurologie & Revalidatie registered on Peppol?

Yes, Dr. Katleen Bruylant - Neurologie & Revalidatie is registered on the Peppol network with ID 0208:0741749694.

What is the enterprise number of Dr. Katleen Bruylant - Neurologie & Revalidatie?

The enterprise number of Dr. Katleen Bruylant - Neurologie & Revalidatie is BE0741749694.

When was Dr. Katleen Bruylant - Neurologie & Revalidatie founded?

Dr. Katleen Bruylant - Neurologie & Revalidatie was founded on 20 January 2020.

Who are the directors of Dr. Katleen Bruylant - Neurologie & Revalidatie?

According to the 2025 annual accounts, the directors of Dr. Katleen Bruylant - Neurologie & Revalidatie are: Kathleen Bruylant.

Is Dr. Katleen Bruylant - Neurologie & Revalidatie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 January 2020; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Katleen Bruylant - Neurologie & Revalidatie make in 2025?

Dr. Katleen Bruylant - Neurologie & Revalidatie posted a profit after taxes of € 62,002 in financial year 2025.

What is the revenue of Dr. Katleen Bruylant - Neurologie & Revalidatie?

As a small company, Dr. Katleen Bruylant - Neurologie & Revalidatie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 101,787.

Dr. Katleen Bruylant - Neurologie & Revalidatie - Gent

Dossier Dr. Katleen Bruylant - Neurologie & Revalidatie, printed on 2 November 2026 from databakkes.be/en/0741749694/dr-katleen-bruylant-neurologie-revalidatie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 18 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Dr. Katleen Bruylant - Neurologie & Revalidatie from Gent, company number BE0741749694, closed financial year 2025 with a result of € 62,002 after tax. For that financial year Dr. Katleen Bruylant - Neurologie & Revalidatie recorded a gross margin of € 101,787 and equity of € 67,002. Compared with financial year 2024, the result moved from € 50,220 to € 62,002. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 1, 2026.

What it is worth Growing

€ 67,002

▲ 21% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 62,002

▲ 23% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 6,662

▼ 1% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 50,220 paid out

81 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 4,297

▼ 46% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 5,050

▼ 73% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 1,532

▲ 156% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 5,871

▲ 43% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 49,870 Gross margin 2022: € 49,870 First fiscal year in the series	€ 81,194 Gross margin 2023: € 81,194 ▲ 63% vs 2022 (€ 49,870) Favourable step	€ 86,796 Gross margin 2024: € 86,796 ▲ 7% vs 2023 (€ 81,194) Favourable step	€ 101,787 Gross margin 2025: € 101,787 ▲ 17% vs 2024 (€ 86,796) Favourable step	▲ 17%
Profit after taxes	€ 34,255 Profit after taxes 2022: € 34,255 First fiscal year in the series	€ 50,175 Profit after taxes 2023: € 50,175 ▲ 46% vs 2022 (€ 34,255) Favourable step	€ 50,220 Profit after taxes 2024: € 50,220 Unchanged (€ 50,175) Favourable step	€ 62,002 Profit after taxes 2025: € 62,002 ▲ 23% vs 2024 (€ 50,220) Favourable step	▲ 23%
Equity	€ 126,683 Equity 2022: € 126,683 First fiscal year in the series	€ 88,858 Equity 2023: € 88,858 ▼ 30% vs 2022 (€ 126,683) Unfavourable step	€ 55,220 Equity 2024: € 55,220 ▼ 38% vs 2023 (€ 88,858) Unfavourable step	€ 67,002 Equity 2025: € 67,002 ▲ 21% vs 2024 (€ 55,220) Favourable step	▲ 21%
Total debts	€ 22,213 Total debts 2022: € 22,213 First fiscal year in the series	€ 32,832 Total debts 2023: € 32,832 ▲ 48% vs 2022 (€ 22,213) Unfavourable step	€ 68,487 Total debts 2024: € 68,487 ▲ 109% vs 2023 (€ 32,832) Unfavourable step	€ 39,575 Total debts 2025: € 39,575 ▼ 42% vs 2024 (€ 68,487) Favourable step	▼ 42%
Cash	€ 19,677 Cash 2022: € 19,677 First fiscal year in the series	€ 5,942 Cash 2023: € 5,942 ▼ 70% vs 2022 (€ 19,677) Unfavourable step	€ 6,717 Cash 2024: € 6,717 ▲ 13% vs 2023 (€ 5,942) Favourable step	€ 6,662 Cash 2025: € 6,662 ▼ 1% vs 2024 (€ 6,717) Unfavourable step	▼ 1%
Land & buildings	€ 65,257 Land & buildings 2022: € 65,257 First fiscal year in the series	€ 59,536 Land & buildings 2023: € 59,536 ▼ 9% vs 2022 (€ 65,257) Unchanged	€ 51,917 Land & buildings 2024: € 51,917 ▼ 13% vs 2023 (€ 59,536) Unchanged	€ 44,298 Land & buildings 2025: € 44,298 ▼ 15% vs 2024 (€ 51,917) Unchanged	▼ 15%
Retained profit	€ 121,683 Retained profit 2022: € 121,683 First fiscal year in the series	€ 83,858 Retained profit 2023: € 83,858 ▼ 31% vs 2022 (€ 121,683) Unfavourable step	€ 50,220 Retained profit 2024: € 50,220 ▼ 40% vs 2023 (€ 83,858) Unfavourable step	€ 62,002 Retained profit 2025: € 62,002 ▲ 23% vs 2024 (€ 50,220) Favourable step	▲ 23%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 88,000 Dividend 2023: € 88,000 ▲ € 87,200 vs 2022 (€ 800) Unchanged	€ 83,858 Dividend 2024: € 83,858 ▼ 5% vs 2023 (€ 88,000) Unchanged	€ 50,220 Dividend 2025: € 50,220 ▼ 40% vs 2024 (€ 83,858) Unchanged	▼ 40%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 18,824 Bank debt 2024: € 18,824 Unchanged (€ 0) Unfavourable step	€ 5,050 Bank debt 2025: € 5,050 ▼ 73% vs 2024 (€ 18,824) Favourable step	▼ 73%
Balance sheet total	€ 148,897 Balance sheet total 2022: € 148,897 First fiscal year in the series	€ 121,690 Balance sheet total 2023: € 121,690 ▼ 18% vs 2022 (€ 148,897) Unchanged	€ 123,707 Balance sheet total 2024: € 123,707 ▲ 2% vs 2023 (€ 121,690) Unchanged	€ 106,577 Balance sheet total 2025: € 106,577 ▼ 14% vs 2024 (€ 123,707) Unchanged	▼ 14%

Key figures of Dr. Katleen Bruylant - Neurologie & Revalidatie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Katleen Bruylant - Neurologie & Revalidatie?

What happened at Dr. Katleen Bruylant - Neurologie & Revalidatie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 1, 2026 New annual accounts for financial year 2025: profit of € 62,002 (▲ 23% vs 2024). Source: NBB ↗
Jan 20, 2020 New establishment in Eeklo. KBO
Jan 20, 2020 Start of the company according to the CBE. KBO

In short

From € 34,255 profit in 2022 to € 62,002 profit in 2025.

Paid € 73,704 in corporate taxes since 2022.

Best year ever: 2025, with € 62,002 profit.

Paid out € 222,879 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Kathleen Bruylant

Dr. Katleen Bruylant - Neurologie & Revalidatie

Behind Dr. Katleen Bruylant - Neurologie & Revalidatie is Kathleen Bruylant.

Directors

According to the 2025 annual accounts

Kathleen Bruylant

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Maurice Maeterlinckstraat 14

9000 Gent

2.299.706.880

Ringlaan 15

9900 Eeklo

Active since 20 January 2020

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0741.749.694
VAT number: BE 0741.749.694
Registered office: Maurice Maeterlinckstraat 14, 9000 Gent
Names & denominations: Dr. Katleen Bruylant - Neurologie & Revalidatie
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 20 January 2020
Peppol: Active · Active since 8 Dec 2025

View on CBE Public ↗ Annual accounts (NBB) ↗